Merck and Ridgeback make pact with UNICEF for antiviral COVID-19 medicine supply
![](/46/pdcnewsitem/11/59/67/2DG39GP@0.25x.jpg)
The agreement will enable millions of patients in more than 100 low- and middle-income countries to gain access to molnupiravir
Merck (also known as MSD outside the US and Canada), and Ridgeback Biotherapeutics have signed a long-term supply agreement with the UNICEF to facilitate broad global access for molnupiravir, an investigational oral antiviral COVID-19 medicine.
In anticipation of positive clinical trial results and the potential for regulatory authorisation or approval, Merck manufactured 10 million courses of molnupiravir — a therapy which can play a significant role in global efforts to address the pandemic — at risk, by the end of 2021. The company says it it expects to produce at least 20 million courses in 2022.
This latest agreement will see Merck allocate up to 3 million courses throughout the first half of 2022 to UNICEF for distribution in more than 100 low- and middle-income countries following regulatory authorisations.
According to Robert M. Davis, CEO and president, Merck, patients from these countries will "gain access at the same time as patients in countries with higher incomes".
To accelerate broad global access for molnupiravir upon authorisation or approval, Merck’s supply and access approach includes investing at risk to produce millions of courses of the therapy, tiered pricing based on the ability of governments to finance healthcare, granting voluntary licences to generic manufacturers and to the Medicines Patent Pool to help increase affordable supply in the developing world, and making supply agreements with governments and other organisations.
Merck is developing molnupiravir in collaboration with Ridgeback Biotherapeutics and it has already been authorised for use in more than 10 countries, including in the US, UK and Japan.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance